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http://dx.doi.org/10.1016/j.kjms.201Abstract Cancer-associated fibroblast (CAF) is one of the most crucial components of the
tumor microenvironment to promote the invasiveness of cancer cells. The interactions
between cancer cells and CAFs are bidirectional. Our recent study showed that up-
regulations of chemokine (C-C motif) ligand 2 (CCL2), chemokine (C-C motif) ligand 26
(CCL26), interleukin 6 (IL6), and lysyl oxidase-like 2 (LOXL2) genes in cancer cells were parts
of the common effects of CAFs on hepatocellular carcinoma (HCC) cells to promote prolifera-
tion, migration and invasion of cancer cells. However, the subject of how HCC cells to influ-
ence the gene expressions of CAFs still needs to be clarified. The purpose of this study was
to investigate this issue. Two human HCC (HCC24/KMUH, HCC38/KMUH) and two human CAF
cell lines (F26/KMUH, F28/KMUH) were studied. Influence of HCC38/KMUH cancer cells on
differential expressions of genes in F28/KMUH CAFs was detected by microarray to select
target genes for further analysis. Both HCC cell lines increased proliferation (all p < 0.005)
and migration (all p < 0.0001) of two CAF cell lines. HCC24/KMUH cancer cells had stronger
ability to promote migration of F26/KMUH CAFs than HCC38/KMUH cancer cells did
(p < 0.0001). Eleven up-regulated cancer-promoting genes, including apelin (APLN), CCL2,
CCL26, fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), IL6, mucin 1
(MUC1), LOXL2, platelet-derived growth factor alpha polypeptide (PDGFA), phosphoglycerate
kinase 1 (PGK1), and vascular endothelial growth factor A (VEGFA) detected by microarray
showed good correlation with results of quantitative reverse transcriptase-polymerase chainter and Division of Hepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical
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Influence of HCC on gene expressions of CAF 313reaction study. Among these genes, HCC24/KMUH cancer cells had same tendency of effects on
differential expressions of genes in F28/KMUH CAFs as HCC38/KMUH cancer cells did. However,
the responses of F26/KMUH CAFs to different HCC cell lines were variable. Only PGK1 gene was
consistently up-regulated and PDGFA gene was consistently down-regulated caused by both
HCC cell lines in F26/KMUH CAFs. Besides PGK1 gene, HCC38/KMUH cancer cells only up-
regulated APLN, LOXL2, and VEGFA genes and HCC24/KMUH cancer cells only up-regulated
FGF2 gene in F26/KMUH CAFs. In conclusion, HCC cells can promote proliferation and migration
of CAFs. However, the impact of HCC cells on differential expressions of cancer-promoting
genes in CAFs is influenced by the characteristics of CAFs. This implies that blocking single
or several particular cancer-promoting genes in CAFs is unable to become a common stratagem
for the treatment of HCC.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasion and metastasis of malignancy are determined by
the characteristics of cancer cells and the interactions
between the cancer cells and the tumor microenvironment.
Cancer-associated fibroblast (CAF) is one of the most
crucial components of the tumor microenvironment to
promote the growth and invasion of cancer cells [1e5]. The
interactions between cancer cells and CAFs are bidirec-
tional and are initiated from secretion of soluble factors
from cancer cells to enhance the ability of CAFs to secrete
a variety of tumor-promoting factors [3]. Hepatocellular
carcinoma (HCC) is the most common primary liver cancer
and ranks globally as the third to fourth leading cause of
cancer-related death [6,7]. Understanding the HCCeCAF
interactions may help us to target the tumor microenvi-
ronment and thus to improve the prognosis of HCC [4]. Our
recent study showed that up-regulations of chemokine (C-C
motif) ligand 2 (CCL2), C-C motif ligand 26 (CCL26), inter-
leukin 6 (IL6), and lysyl oxidase-like 2 (LOXL2) genes in
cancer cells were parts of the common effects of CAFs on
HCC cells to promote proliferation, migration, and invasion
of cancer cells [8]. Although lysophosphatidic acid secreted
from HCC cells had been demonstrated to accelerate HCC
progression by recruiting peritumoral tissue fibroblasts and
promoting their transdifferentiation into CAFs [5], the
subject of how HCC cells to influence the gene expressions
of CAFs still need to be clarified. Moreover, the charac-
teristics of CAFs have significant individual/intrinsic
differences [9]. This suggests that the responses of
different CAFs to different HCC cells stimulations may be
variable. The purpose of this study was to investigate
whether different human CAF cell lines had different
responses to different human HCC cell lines. All gene names
are according to the official symbols from the HUGO Gene
Nomenclature Committee.
Methods
Cell lines
Two CAF cell lines (F26/KMUH, F28/KMUH) newly estab-
lished from patients with HCC in our institution and twohuman HCC cell lines (HCC24/KMUH, HCC38/KMUH) used in
our previous studies [10e12] were investigated. CAF cell
lines were verified by positive stain for fibroblast activation
protein (ENZO Life Sciences International, Inc., Butler Pike,
Plymouth Meeting, PA, USA), a-smooth muscle actin (Sigma-
Aldrich, St. Louis, MO, USA) and chemokine (C-X-C motif)
ligand 12 (CXCL12; R & D Systems, Inc., Minneapolis, MN,
USA). Both CAF cell lines were also verified to have
capacities to penetrate the Matrigel. All procedures to
establish these cell lines were approved by the Institutional
Review Board of our hospital and patients were given
informed consent. All cultures were maintained at 37C in
a humidified atmosphere of 5% CO2 and 95% air. The serum-
containing culture medium consisted of 10% fetal bovine
serum, 90% DME/HIGH glucose, supplemented with 20 mM
L-glutamine, 100 U/mL penicillin and 100 mg/mL strepto-
mycin (HyClone, Logan, UT, USA).
Influence of HCC cells on proliferation of CAFs
CAFs from each cell line were seeded in three 24-well cell
culture insert companion plates (18 wells/plate, 1  105
cells/well). Cancer cells from each cell line were seeded in
36 culture inserts (2  105 cells/insert) with transparent
polyethylene terephthalate membrane (pore size: 0.4 mm,
BD Falcon, Cell Culture Inserts, BD Biosciences, Mississauga,
Ontario, Canada) using two new 24-well companion plates.
Both CAFs and cancer cells were incubated with serum-
containing medium for 24 hours, then all medium was
replaced with serum-free medium and the inserts were
transferred to CAFs containing wells. The cells were incu-
bated for another 48 hours. Then the inserts were removed
and CAFs in each well were analysis. The premixed WST-1
cell proliferation reagent (Clontech Laboratories, Inc.,
A Takara Bio Company, Mountain View, CA, USA) was
applied. The experimental procedures were carried out
following the manufacturer’s protocols. The cells were
incubated with reagent for 4 hours at 37C in a humidified
atmosphere of 5% CO2 and 95% air. After that, 0.1 mL
suspension in each well was transferred to 96-well plate for
automated microplate reader (MRX, Dynex Technologies,
Inc., Chantilly, VA, USA) analysis. The absorbance was
measured at 450 nm wavelength (reference wavelength,
630 nm).
314 Z.-Y. Lin, W.-L. ChuangInfluence of HCC cells on migration of CAFs
For each CAF cell line, cancer cells from each cell line
seeded in eight wells (1  105 cells/well) of 24-well cell
culture insert companion plate were incubated with serum-
containing medium for 24 hours. Then the medium of each
well was replaced with serum-containing medium again and
the CAFs containing insert (3000 cells/insert, with trans-
parent polyethylene terephthalate membrane, pore size:
8 mm, BD Falcon Cell Culture Inserts, BD Biosciences) with
serum-free medium was transferred to cancer cells con-
taining wells. An additional eight CAFs containing inserts
with serum-free medium (3000 cells/insert) were trans-
ferred to wells with serum-containing medium but without
cancer cells as control group. The cells were incubated for
further 18 hours. Then the cells inside the insert were
wiped with cotton-swabs and removed. The cells that
migrated through the pores and adhered onto the outer
side of the insert were stained by the technique of Liu-stain
[13]. Whole migrated cells in each insert were counted at
100 magnification.Influence of HCC cells on differential expressions of
genes in CAFs
Microarray experiment
CAFs from each cell line were seeded in two six-well cell
culture insert companion plates (2  105 cells/well) and
cancer cells from each cell line were seeded in 6 culture
inserts (2  105 cells/insert, with transparent poly-
ethylene terephthalate membrane, pore size: 0.4 mm, BD
FalconCell Culture Inserts, BD Biosciences) using a new
six-well companion plate. Bothe cancer cells and CAFs
were incubated with serum-containing medium for 24
hours, then all medium was replaced with serum-free
medium and the inserts were transferred to CAFs con-
taining wells. The wells without insert were used as
control group. The cells were incubated for further 48
hours. Then total RNA in each well were extracted by
Trizol Reagent (Invitrogen, Life Technologies Corporation,
Grand Island, NY 14072 USA), and followed by RNAeasy
Mini Kit (QIAGEN GmbH, Hilden, Germany). Purified RNA
was quantified by OD260 nm by a ND-1000 spectropho-
tometer (Nanodrop Technology, Wilmington, DE, USA) and
qualified by Bioanalyser 2100 (Agilent Technology, Santa
Clara, CA, USA). To select candidate genes for further
quantitative reverse transcription polymerase chain
reaction (RT-PCR) analysis, influence of HCC38/KMUH
cells on differential expressions of genes in F28/KMUH
cells was investigated by microarray (Agilent SurePrint G3
Human GE 8  60 k, Agilent Technologies, Santa Clara,
CA, USA). Microarray experimental procedures were
carried out following the manufacturer’s protocols and
were the same as in our previous study [10]. Control group
was labeled with Cy3-CTP and the experimental group
was labeled with Cy5-CTP (CyDye, PerkinElmer, Waltham,
MA, USA) during the in vitro transcription process. The A
value representing the average signal of two channels
(Cy5 and Cy3) of the spot is calculated by the formula
(log2 Cy5 BgSubSignal þ log2 Cy3 BgSubSignal)/2. The Cy5
(or Cy3) BgSubSignal was calculated by the formula: meansignal intensity of Cy5 (or Cy3) e mean background light
intensity of Cy5 (or Cy3). The Cy5 (or Cy3) BgUsed indi-
cated the mean background intensity of Cy5 (or Cy3)
channel. The M-value was calculated by the formula: log2
(Cy5 BgSubSignal/Cy3 BgSubSignal). If one gene was
detected by multiple probes, the average A and M values
were calculated for analysis. Genes with both Cy3
BgSubSignal/Cy3 BgUsed and Cy5 BgSubSignal/Cy5 BgUsed
values less than one or the average A value <6 were
excluded in the selection of differential expressions of
genes because of the high probability of false results in
these groups. Selection of differentially expressed genes
was based on the absolute M value (log2 gene expression
fold change)  1.Quantitative RT-PCR experiment
For quantitative RT-PCR study, specific oligonucleotide primer
pairs were selected from Roche Universal ProbeLibrary, Roche
Diagnostics Ltd., Taipei, Taiwan and used for real-time PCR.
Theprocedures for real-timePCRreactionswere thesameas in
our previous studies [10e12]. At each real-time PCR run, the
data were automatically analyzed by the system and an
amplification plot was generated for each cDNA sample. From
each of these plots, the LightCycler3 Data analysis software
automatically calculates CP value (crossing point, the turning
point corresponds to the first maximum of the second deriva-
tive curve), which implies the beginning of exponential
amplification. The fold expression or repression of the target
gene relative to reference gene in each samplewas calculated
by the formula: gene expression fold changeZ 2CP, where
CP Z CPtarget gene e CPreference gene, and CP Z CPtest
sample e CPcontrol sample. The housekeeping gene TATA box
binding protein (TBP) was used as reference gene. Eleven
genes were selected for quantitative RT-PCR study. The PCR
primers used were 50-AATCCAGCCCACTTACAGGTTTTC-30
sense primer and 50-TAGCAGAAGACACCCACCAAGG-30 anti-
sense primer for apelin (APLN), 50-AGTCTCTGCCGCCCTTCT-30
sense primer and 50-GTGACTGGGGCATTGATTG-30 anti-sense
primer for CCL2, 50-CTGGACCTGGGTGCGAAGC-30 sense
primer and 50-TGGATGGGTACAGACTTTCTTGCC-30 antisense
primer for CCL26, 50-CCCGCCATACATTAAGGAGCAG-30 sense
primer and 50-GGTTAGTTGAGGTCAGGTGAGG-30 antisense
primer for fibroblast growth factor 1 (FGF1), 50-TACAGCAG-
CAGCCTAGCAACTC-30 sense primer and 50-TTCGGCAACAGCA-
CACAAATCC-30 antisense primer for fibroblast growth factor 2
(FGF2), 50-TTCTCCACAAGCGCCTTC-30 sense primer and 50-AG
CAGGCAACACCAGGAG-30 antisense primer for IL6, 50-GCAG
CAGCCTCTCTTACACAAAC-30 sense primer and 50-AGAACCT
GAGTGGAGTGGAATGG-30 antisense primer for mucin 1
(MUC1), 50-AGTGACTCATCTTCCTGTTGTTCC-30 sense primer
and 50-GACCCTGGTTATAGCACCGTTG-30 antisense primer for
LOXL2, 50-GCAGTCAGATCCACAGCATC-30 sense primer and 50-
TCCAAAGAATCCTCACTCCCTA-30 antisenseprimer forplatelet-
derived growth factor alpha polypeptide (PDGFA), 50-GCCAGG
AACCCTTAAACAGTTG-30 sense primer and 50-AATGGGATCTT
GAAGAATGTATGC-30 antisense primer for phosphoglycerate
kinase 1 (PGK1), 50-GTGGTTGACCTTCCTCCATCCC-30 sense
primer and 50-GATCCTGCCCTGTCTCTCTG-30 antisense primer
for vascular endothelial growth factor A (VEGFA), and 50-
CAATTTAGTAGTTATGAGCCAGAG-30sense primer and 50-
TTCTGCTCTGACTTTAGCAC-30 antisense primer for TBP.
Figure 2. Influence of hepatocellular carcinoma cells
(HCC24/KMUH, HCC38/KMUH) on migration of cancer-
associated fibroblasts (F26/KMUH, F28/KMUH). In all experi-
ments, eight replicate wells were used to determine the mean
and the standard deviation (SD). The two-tailed unpaired t test
was applied for statistical analysis. Bars indicate SD.
(a,b,c,d,e) p < 0.0001; (f) p Z 0.85. F26/KMUH, F28/
KMUHZ human cancer-associated fibroblast cell lines; HCC24/
KMUH, HCC38/KMUH Z human hepatocellular carcinoma cell
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The two-tailed unpaired t test was used to analyze the
significant difference between two means. The statistical
significance was defined as p < 0.05.
Results
Proliferative and migratory experiments
Both HCC cell lines significantly increased proliferative (all
p < 0.005; Fig. 1) and migratory abilities (all p < 0.0001;
Fig. 2) of both CAF cell lines. There was no significant
difference between different HCC cell lines to increase the
proliferation of CAFs (all p > 0.3). HCC24/KMUH cancer
cells had stronger ability to promote migration of F26/
KMUH CAFs than HCC38/KMUH cancer cells did
(p < 0.0001).
Microarray and quantitative RT-PCR experiments
HCC38/KMUH cancer cells up-regulated 232 genes and
down-regulated 356 genes in F28/KMUH CAFs. Among these
gene, three chemokine genes (CCL2, CCL26, CXCL1) were
up-regulated. Eleven up-regulated genes (APLN, CCL2,
CCL26, FGF1, FGF2, IL6, MUC1, LOXL2, PDGFA, PGK1,
VEGFA) favored proliferation, migration, invasion, orFigure 1. Influence of hepatocellular carcinoma cells
(HCC24/KMUH, HCC38/KMUH) on proliferation of cancer-
associated fibroblasts (F26/KMUH, F28/KMUH). The premixed
WST-1 cell proliferation reagent was applied for investigation.
The absorbance was measured at 450 nm wavelength (refer-
ence wavelength, 630 nm). In all experiments, 18 replicate
wells were used to determine the mean and the standard
deviation (SD). The two-tailed unpaired t test was applied for
statistical analysis. Bars indicate SD. (a) p Z 0.0009; (b)
p Z 0.0013; (c) p > 0.3; (d,e) p < 0.0001; (f) p > 0.3. F26/
KMUH, F28/KMUH Z human cancer-associated fibroblast cell
lines; HCC24/KMUH, HCC38/KMUH Z human hepatocellular
carcinoma cell lines.
lines.angiogenesis of HCC were selected for quantitative RT-PCR
analysis. There were good correlations between results
from quantitative RT-PCR and microarray. Among these
tested genes (Table1), HCC24/KMUH cancer cells had same
tendency of effects as HCC38/KMUH cancer cells did on
differential expressions of genes in F28/KMUH CAFs.
However, the responses of F26/KMUH CAFs to both HCC cell
lines were not consistent with F28/KMUH CAFs and were
variable. Only PGK1 gene in F26/KMUH CAFs was consis-
tently up-regulated caused by both HCC cell lines as in F28/
KMUH CAFs. On the contrary, PDGFA gene in F26/KMUH
CAFs was consistently down-regulated, which was caused
by both HCC cell lines. For the other tested genes in F26/
KMUH CAFs, HCC38/KMUH cancer cells up-regulated APLN,
LOXL2, and VEGFA genes and down-regulated FGF1 and
MUC1 genes, and HCC24/KMUH cancer cells up-regulated
FGF2 gene and down-regulated CCL2 gene.Discussion
The present study showed that HCC cells could promote
proliferation and migration of CAFs. Since the characteris-
tics of CAFs have significant individual/intrinsic differences
[9], our results from migratory experiment and expressions
of genes also showed that the effects of HCC cells on CAFs
were influenced by the characteristics of CAFs. These
results suggested that the mechanisms for HCC cells to
promote proliferation and migration of CAFs were complex.
Nevertheless, consistent up-regulation of PGK1 gene
in both CAF cell lines may be one of the common
Table 1 Influence of hepatocellular carcinoma cells on gene expression fold change of cancer-associated fibroblasts.
Gene name F26/KMUH influenced by F28/KMUH influenced by
HCC24/KMUH HCC38/KMUH HCC24/KMUH HCC38/KMUH
APLN 1.20 9.76 10.31 9.54
CCL2 0.54 0.81 1.53 4.14
CCL26 1.00 0.95 4.21 4.51
FGF1 0.75 0.54 1.73 1.24
FGF2 1.58 1.19 2.29 2.21
IL6 1.25 1.2 5.13 1.49
MUC1 1.02 0.57 4.21 2.70
LOXL2 1.12 1.78 3.71 2.89
PDGFA 0.51 0.08 4.55 1.48
PGK1 1.58 3.47 3.54 2.51
VEGFA 1.04 2.31 3.15 2.79
All gene names are according to official symbol from HUGO Gene Nomenclature Committee. Gene expression fold change was deter-
mined by quantitative reverse transcriptase-polymerase chain reaction. The housekeeping gene TATA box-binding protein (TBP) was
used as reference gene. The value of gene expression fold change between 0.7 and 1.3 was defined as no significant change, more than
1.3 was defined as up-regulation, less than 0.7 was defined as down-regulation as compared with control. F26/KMUH, F28/
KMUH Z human cancer-associated fibroblast cell lines; HCC24/KMUH, HCC38/KMUH Z human hepatocellular carcinoma cell lines.
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The protein encoded by PGK1 gene is a glycolytic enzyme
that catalyzes the conversion of 1,3-diphosphoglycerate to
3-phosphoglycerate that forms part of the glycolytic
pathway. CAFs overexpression of PGK1 gene has been
shown to have high proliferative index [14]. Besides PGK1
gene, concomitant up-regulation of FGF1, FGF2, IL6, MUC1,
and PDGFA genes in F28/KMUH CAFs may also be the
explanations for HCC cells to promote proliferation of F28/
KMUH CAFs and thus promote cancer progression. The
proteins encoded by FGF1 and FGF2 genes are members of
the fibroblast growth factor family. Up-regulation of FGF1
can inhibit p53-dependent apoptosis and cell cycle arrest
via an intracrine pathway to promote cell survival and
proliferation [15]. Overexpression of FGF1 in CAFs has been
demonstrated to promote migration and invasion in colo-
rectal cancer cells through FGF1/FGFR-3 signaling [16].
FGF2 plays an important role in proliferation, differentia-
tion, and survival of cells of almost all organ systems [16],
and has capacity to promote proliferation of cancer cells
[17]. FGF1 and FGF2 also can induce angiogenesis [17e20].
IL6 can promote survival and proliferation of cells through
activating the STAT3 pathway [21e23]. IL6 can also stimu-
late circulating blood-derived endothelial progenitor cell
angiogenesis [24]. Moreover, CAFs can promote tumor
growth through the paracrine production of secreted IL6
[25]. The protein encoded by MUC1 gene is a trans-
membrane mucin glycoprotein that has been demonstrated
to promote cell survival through STAT3 activation [26], and
invasiveness and metastasis through induction of epithelial
to mesenchymal transition [27]. The protein encoded by
PDGFA gene is a member of the platelet-derived growth
factor family, which is a significant mediator in the prolif-
eration of CAFs [28].
Five genes (APLN, CCL2, CCL26, LOXL2, VEGFA) favored
HCC angiogenesis; invasion and metastasis were also
consistently up-regulated in F28/KMUH CAFs under the
stimulation of both HCC cell lines. Up-regulation of APLN
[29e31] and VEGFA [32,33] genes can promoteangiogenesis. The protein encoded by LOXL2 gene is
a member of the lysyl oxidase family that functions as an
amine oxidase for formation of lysine-derived cross-links
found in collagen and elastin, and can induce epithelial to
mesenchymal transition [34,35]. Overexpression of LOXL2
has been shown to promote tumor cell invasion [35e38].
Chemokines have been proposed as key players in the cross-
talk interactions between cancer cells and CAFs [3]. The
soluble factors released from cancer cells enhance the
ability of the CAFs to secrete a variety of tumor-promoting
chemokines such as CXCL12, CCL2, CCL5, CCL7, CXCL8, and
CXCL14. These chemokines then act back on the cancer
cells to promote their proliferative, migratory, and invasive
properties [3]. The present study showed that CCL2 and
CCL26 genes were consistently up-regulated only in F28/
KMUH CAFs under the stimulations from both HCC cell lines.
CCL2 has been shown to promote adhesion, migration and
invasion of prostate cancer cells partially through its
differential regulation of protein kinase C and MMP 9
signaling [39]. CCL2may also promote progression of human
esophageal and gastric carcinoma through its role in
angiogenesis via macrophage recruitment and activation
[40,41]. The product of CCL26 gene displays chemotactic
activity for eosinophils, which contain preformed vascular
endothelial growth factor in their secretory granules.
Recruitment of eosinophils to tumor sites can promote
angiogenesis [42].
For F26/KMUH CAFs, all tested genes except PGK1 gene
were not consistently up-regulated caused by both HCC cell
lines. However, HCC cells did promote proliferation and
migration of F26/KMUH CAFs. This suggests that other
mechanisms, which need to be further investigated, are
involved in the interactions between F26/KMUH CAFs and
HCC cells.
In conclusion, HCC cells can promote proliferation and
migration of CAFs. However, the impact of HCC cells on
differential expressions of cancer-promoting genes in CAFs
is influenced by the characteristics of CAFs. This implies
that blocking single or several particular cancer-promoting
Influence of HCC on gene expressions of CAF 317genes in CAFs is unable to become a common stratagem for
the treatment of HCC.Acknowledgment
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